Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ENZY.STthis companyEnzymatica AB (publ)	SEK 2.40	-9.05×	3.71×	8.56×	-9.17×	-287.0%	61.5%	-96.9%	-96.3%	-41.8%	-41.7%	-8.9%	0.01×	0.69×	-42.41×	3.65×	0.0%	4	10.82	1	C-
ACE.STAscelia Pharma AB (publ)	SEK 0.53	-4.81×	3.67×	0×	-4.32×	-17.7%	0.0%	0.0%	0.0%	-76.7%	-73.4%	-19.8%	0.01×	0.67×	-13.46×	4.35×	0.0%	1	-8.91	2	C+
ALZCUR.STAlzeCure Pharma AB	SEK 6.46	-4.26×	6.11×	0×	-3.24×	-92.8%	0.0%	0.0%	0.0%	-144.8%	-139.1%	-17.2%	0.16×	0.94×	-180.85×	2.33×	0.0%	5	15.15	3	B+
CLBIO.STCorline Biomedical AB	SEK 12.80	-27.8×	4.33×	53.02×	-27.26×	-165.9%	-185.7%	-185.7%	-192.3%	-15.7%	-15.2%	-4.4%	0×	1.46×	0×	4.98×	0.0%	3	12.35	1	D+
ERMA.STEnorama Pharma AB (publ)	SEK 0.76	-1.77×	-5.66×	48.45×	-2.1×	-104.0%	-2255.6%	-2268.0%	-2743.3%	320.4%	264.9%	-44.7%	0×	0.05×	-4.91×	0.25×	0.0%	2	-29.47	2	C
FLFLUO.STFluoGuide A/S	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Peer median	—	-4.53×	4×	24.22×	-3.78×	-98.4%	-92.9%	-92.9%	-96.2%	-46.2%	-44.3%	-18.5%	0.01×	0.8×	-9.19×	3.34×	0.0%	3	1.72	2	—